| Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2· 4 mg for weight management: a … LB Enebo, KK Berthelsen, M Kankam, MT Lund, DM Rubino, ... The Lancet 397 (10286), 1736-1748, 2021 | 216 | 2021 |
| Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial WT Garvey, AL Birkenfeld, D Dicker, G Mingrone, SD Pedersen, ... Diabetes care 43 (5), 1085-1093, 2020 | 136 | 2020 |
| Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database CL Haase, S Lopes, AH Olsen, A Satylganova, V Schnecke, P McEwan International Journal of Obesity 45 (6), 1249-1258, 2021 | 133 | 2021 |
| Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose … DCW Lau, L Erichsen, AM Francisco, A Satylganova, CW le Roux, ... The Lancet 398 (10317), 2160-2172, 2021 | 118 | 2021 |
| Prevalence of depression in adults with type 2 diabetes in the Basque Country: relationship with glycaemic control and health care costs E Alonso-Morán, A Satylganova, JF Orueta, R Nuño-Solinis BMC Public Health 14, 1-8, 2014 | 85 | 2014 |
| Body mass index and risk of obesity‐related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database CL Haase, KT Eriksen, S Lopes, A Satylganova, V Schnecke, P McEwan Obesity science & practice 7 (2), 137-147, 2021 | 42 | 2021 |
| Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data S Wharton, A Astrup, L Endahl, MEJ Lean, A Satylganova, D Skovgaard, ... International Journal of Obesity 45 (5), 923-933, 2021 | 36 | 2021 |
| Integrated care models: an overview A Satylganova World Health Organisation, 2016 | 35 | 2016 |
| Obesity, cardiovascular risk and healthcare resource utilization in the UK CW le Roux, NV Hartvig, CL Haase, RB Nordsborg, AH Olsen, ... European journal of preventive cardiology 28 (11), 1235-1241, 2021 | 29 | 2021 |
| Efficacy and safety of AM833 for weight loss: a dose-finding trial in adults with overweight/obesity D Lau, L Erichsen, AM Francisco, C Le Roux, B McGowan, S Pedersen, ... Obesity 28, 18-18, 2020 | 11 | 2020 |
| A comprehensive descriptive assessment of obesity related chronic morbidity and estimated annual cost burden from a population-based electronic health record database O Reges, M Leibowitz, A Hirsch, D Dicker, N Finer, CL Haase, ... Israel Journal of Health Policy Research 9, 1-10, 2020 | 7 | 2020 |
| Better noncommunicable disease outcomes: challenges and opportunities for health systems: Croatia country assessment: focus on cardiovascular diseases and diabetes J Tello, A Satylganova, S Stachenko, A Jurgutis, D Mulholland, T Habicht, ... Better noncommunicable disease outcomes: challenges and opportunities for …, 2015 | 6 | 2015 |
| Estimating and interpreting treatment effects in clinical trials for weight management: implications of estimands, intercurrent events and missing data S Wharton, A Astrup, L Endahl, MEJ Lean, A Satylganova, D Skovgaard Int J Obes 45, 923-933, 2021 | 5 | 2021 |
| Better noncommunicable disease outcomes: challenges and opportunities for health systems. Kazakhstan country assessment J Farrington, A Satylganova, S Stachenko, J Tello, FR Pezzella, ... World Health Organization. Regional Office for Europe, 2018 | 5 | 2018 |
| Safety and tolerability of concomitant administration of multiple-dose AM833 with semaglutide 2.4 MG for weight management LB Enebo, KK Berthelsen, M Kankam, MT Lund, DM Rubino, ... Journal of the Endocrine Society 5 (Suppl 1), A26, 2021 | 4 | 2021 |
| A multisectoral approach to the prevention and control of noncommunicable diseases: building the momentum in Belarus T Migal, I Novik, E Zaitsev, A Satylganova, F Mantingh, S Stachenko, ... Public health panorama 1 (01), 69-73, 2015 | 1 | 2015 |
| Body mass index trajectories among people with obesity and association with mortality: Evidence from a large Israeli database O Reges, D Dicker, CL Haase, N Finer, T Karpati, M Leibowitz, ... Obesity Science & Practice 7 (2), 148-158, 2021 | | 2021 |
| Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE Insulin trial G Mingrone, T Garvey, AL Birkenfeld, D Dicker, SD Pedersen, ... DIABETOLOGIA 62, S278-S278, 2019 | | 2019 |
| Effect of liraglutide 3.0 mg on glycaemic parameters in adults with overweight/obesity and type 2 diabetes treated with basal insulin: SCALE insulin trial D Dicker, AL Birkenfeld, T Garvey, G Mingrone, SD Pedersen, ... DIABETOLOGIA 62, S277-S278, 2019 | | 2019 |
| EFFICACY AND SAFETY OF LIRAGLUTIDE 3.0 mg IN INDIVIDUALS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (T2D) TREATED WITH BASAL INSULIN: THE SCALE INSULIN TRIAL WT Garvey, A Birkenfeld, D Dicker, G Mingrone, S Pedersen, ... Journal of the ASEAN Federation of Endocrine Societies 34 (2), 12-12, 2019 | | 2019 |
